SG Americas Securities LLC Acquires 323,747 Shares of Day One Biopharmaceuticals, Inc. $DAWN

SG Americas Securities LLC lifted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 1,228.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 350,092 shares of the company’s stock after acquiring an additional 323,747 shares during the quarter. SG Americas Securities LLC’s holdings in Day One Biopharmaceuticals were worth $3,263,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of DAWN. Federated Hermes Inc. bought a new stake in Day One Biopharmaceuticals during the third quarter worth about $39,000. Ameritas Investment Partners Inc. grew its holdings in Day One Biopharmaceuticals by 44.5% in the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after purchasing an additional 2,264 shares during the period. Quarry LP bought a new position in shares of Day One Biopharmaceuticals during the third quarter valued at approximately $49,000. Prudential Financial Inc. bought a new position in shares of Day One Biopharmaceuticals during the second quarter valued at approximately $69,000. Finally, Lazard Asset Management LLC purchased a new position in shares of Day One Biopharmaceuticals during the second quarter valued at approximately $89,000. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN opened at $21.45 on Friday. The firm’s 50 day moving average price is $15.40 and its 200-day moving average price is $10.90. Day One Biopharmaceuticals, Inc. has a 52-week low of $5.64 and a 52-week high of $21.47. The company has a market cap of $2.22 billion, a PE ratio of -20.83 and a beta of -1.74.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. The firm had revenue of $53.72 million for the quarter, compared to the consensus estimate of $49.81 million. On average, analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on DAWN. JonesTrading cut Day One Biopharmaceuticals from a “buy” rating to a “hold” rating and boosted their price target for the stock from $20.00 to $21.50 in a research report on Friday, March 6th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Friday, March 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. Needham & Company LLC cut Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 6th. Finally, Zacks Research downgraded Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $23.29.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 15,459 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $179,324.40. Following the transaction, the chief executive officer directly owned 204,603 shares of the company’s stock, valued at $2,373,394.80. This represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Charles N. York II sold 6,065 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $70,354.00. Following the sale, the chief financial officer directly owned 312,025 shares in the company, valued at $3,619,490. This trade represents a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 36,461 shares of company stock worth $422,948. Insiders own 6.20% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.